Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor

Completed · Phase 2

Conditions studied: Sarcoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have relapsed or refractory Ewing's sarcoma or peripheral primitive neuroectodermal tumor or desmoplastic small round cell tumor.

Key facts

Study ID

NCT00055952

Run by

Daiichi Sankyo

Starts

2003-01-01

Expected to finish

2006-04-01

Last updated by the study team

2012-05-16

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Colorado Cancer Center at University of Colorado Health Sciences Center — Denver, Colorado, United States
• Nemours Children's Clinic — Jacksonville, Florida, United States
• Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• St. Jude Children's Research Hospital — Memphis, Tennessee, United States
• Medical City Dallas Hospital — Dallas, Texas, United States
• Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas — Dallas, Texas, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• Hospital for Sick Children — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.